Saturday 17 October 2026
Export MIST’s income statement to Excel — free account
Milestone Pharmaceuticals Inc.
MIST Healthcare Biotechnology
Milestone Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, up 54.6% from fiscal 2023. In the quarter to June 2026, revenue fell 62.7%, EPS fell 5.00%, free cash flow fell 80.8% and total debt rose 7.19%, each against the same quarter a year earlier.
0.71
0.09
−11.25%
Follow MIST
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 1 | — | — | — | — | — | — |
P/E ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Altman Z-Score |
(4.65) | — | (6.95) | 5.87 | 20.31 | — | — | — | — |
P/S ratio |
8.07 | — | 3.68 | 0.00 | 0.00 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(9.77) | — | (13.55) | (2.69) | 14.38 | — | — | — | — |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Beneish M-Score |
— | — | 9.07 | 15.89 | — | — | — | — | — |
P/Operating CF |
(13.26) | — | (7.89) | (13.37) | (22.14) | — | — | — | — |
P/B ratio |
4.06 | — | 4.61 | 2.59 | 2.43 | — | — | — | — |
Price to Tangible BV |
4.06 | — | 4.61 | 2.59 | 2.43 | — | — | — | — |
EV/Sales |
5.75 | — | 2.91 | 0.00 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(2.46) | — | (1.32) | (2.08) | (4.83) | — | — | — | — |
EV/FCF |
(2.45) | — | (1.31) | (2.07) | (4.77) | — | — | — | — |
Quick Ratio |
7.81 | 8.76 | 9.58 | 10.66 | 16.87 | 23.14 | 14.42 | 19.05 | 16.84 |
Current Ratio |
8.01 | 9.10 | 10.11 | 11.70 | 17.55 | 24.14 | 14.71 | 19.42 | 17.17 |
Net Debt/EBITDA |
0.79 | 0.39 | 0.27 | 1.05 | 2.64 | 2.80 | 2.07 | 3.61 | 3.26 |
Debt/Assets |
50.36% | 70.67% | 66.16% | 2.68% | 0.40% | 0.46% | 0.15% | 0.00% | 0.00% |
Debt/Equity |
1.37 | 4.06 | 2.97 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.00 | 0.01 | 0.05 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.78 | 0.69 | 0.78 | 0.90 | 0.78 | 1.02 | 0.93 | 0.91 | 1.00 |
Capex/Depreciation |
(2.65) | (0.31) | (1.22) | (3.06) | 0.00 | 0.00 | (10.87) | (0.50) | (4.50) |
Interest Coverage |
(16.19) | (11.76) | (23.92) | (47.56) | (195.79) | (69.85) | (22.30) | (33.50) | (44.45) |
| (229.65%) | (277.55%) | (143.61%) | (65.26%) | (33.52%) | (38.73%) | (185.00%) | 52.50% | 18.31% | |
| (66.71%) | (55.09%) | (79.73%) | (60.09%) | (31.76%) | (36.55%) | (52.22%) | (40.09%) | (13.98%) | |
ROIC |
0.00% | 0.00% | (7,071.53%) | (991.65%) | 0.00% | (2,105.90%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(64.05%) | (62.91%) | (90.32%) | (88.57%) | (38.14%) | (34.98%) | (48.20%) | (27.75%) | (31.12%) |
Average Days of Receivables |
753.61 | 0.00 | 1,170.92 | 64.39 | 3.09 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
1,171.28% | 0.00% | 3,105.20% | 796.58% | 257.81% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,117.34% | 0.00% | 1,593.20% | 314.36% | 82.66% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
482.60% | 0.00% | 953.40% | 180.96% | 48.53% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.24 | — | 0.19 | 0.37 | 0.41 | — | — | — | — |
Graham Number |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(39.11%) | — | (77.22%) | (33.83%) | (15.57%) | — | — | — | — |
Free Cash Flow Yield |
(29.12%) | — | (60.19%) | (30.74%) | (12.28%) | — | — | — | — |
Revenue per Share |
0.02 | 0.00 | 0.02 | 0.12 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.58) | (0.46) | (1.08) | (1.24) | (0.79) | (1.73) | (3.24) | (65.93) | (34.00) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (0.03) | (0.02) | (0.15) |
Free Cash Flow per Share |
(0.59) | (0.46) | (1.08) | (1.24) | (0.79) | (1.73) | (3.27) | (65.95) | (34.16) |
Cash per Share |
1.26 | 1.12 | 1.54 | 1.52 | 2.73 | 4.85 | 7.59 | 269.35 | 113.65 |
Shareholders Equity per Share |
0.50 | 0.21 | 0.39 | 1.56 | 2.69 | 4.88 | 7.28 | (172.96) | (139.86) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.50 | 0.21 | 0.39 | 1.56 | 2.69 | 4.88 | 7.28 | (172.96) | (139.86) |
Free Cash Flow |
(49.34) | (28.88) | (46.54) | (52.74) | (33.22) | (50.73) | (51.56) | (21.05) | (8.09) |
Working Capital |
97.94 | 65.80 | 65.81 | 65.66 | 112.15 | 142.53 | 114.17 | 83.52 | 25.95 |
Capital Expenditures |
(0.30) | (0.03) | (0.11) | (0.27) | — | — | (0.41) | 0.00 | (0.04) |
Net Current Asset Value |
40.13 | 11.57 | 14.58 | 63.67 | 111.67 | 141.83 | 113.99 | (55.24) | (33.15) |
EV/EBIT |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.20 | 0.00 | 0.11 | 0.05 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.22 | 0.53 | 0.33 | 0.35 | 0.43 | 0.31 | 0.09 | 0.33 | 0.23 |
Cash ROIC |
(24.08%) | (21.21%) | (35.11%) | (39.68%) | (14.62%) | (17.73%) | (21.95%) | (68.42%) | 130.30% |
Accounts Receivable Turnover |
0.66 | 0.00 | 0.49 | 9.91 | 85.71 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
2.34 | 2.35 | 2.05 | 0.50 | 0.18 | 0.24 | 0.32 | 0.25 | 0.61 |
Average Payables |
10.42 | 7.12 | 6.16 | 6.10 | 6.23 | 6.96 | 6.24 | 3.04 | 3.04 |
Average Assets |
94.53 | 75.36 | 74.85 | 97.17 | 134.91 | 136.70 | 105.75 | 57.84 | 57.84 |
Average Common Equity |
27.46 | 14.96 | 41.56 | 89.47 | 127.86 | 129.02 | 29.85 | (44.16) | (44.16) |
Columns are period end dates